Caribou Biosciences, Inc. Income Statement
CRBU|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Caribou Biosciences, Inc. reported $11M in revenue and $148M in net loss for FY2025. Revenue has grown at a 17.8% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $11.2M | $34.5M | $13.9M | $9.6M | $5.8M |
| SG&A Expense | $37.9M | $38.5M | $38.0M | $24.3M | $16.5M |
| R&D Expense | $109.4M | $112.1M | $82.2M | $52.3M | $23.6M |
| Operating Income | -$148.3M | -$116.1M | -$106.4M | -$67.0M | -$34.3M |
| Interest Expense | - | - | - | - | $4.0K |
| Income Tax | -$550.0K | $193.0K | $70.0K | $321.0K | -$7.5M |
| Net Income | -$148.1M | -$102.1M | -$99.4M | -$66.9M | -$23.4M |
| EPS (Basic) | -$1.65 | -$1.38 | -$1.64 | -$2.11 | - |
| EPS (Diluted) | -$1.65 | -$1.38 | -$1.64 | -$2.11 | -$2.80 |
| Shares Outstanding | 92.4M | 88.4M | 61.0M | 60.3M | 9.7M |
| Operating Margin | -1329.4% | -336.6% | -768.2% | -697.8% | -592.7% |
| Profit Margin | -1327.4% | -296.1% | -717.8% | -697.3% | -404.8% |